STAAR Surgical Company (STAA): Product News News

STAA – Announces FDA approval of the PMA Supplement for the Visian Toric ICL for the correction of myopia with astigmatism.

Key Facts Surrounding This News Item

  • STAA had a POWR Rating of A (Strong Buy) coming into today.
  • STAA was 0.08% above its 10-Day Moving Average coming into today.
  • STAA was 5.83% above its 20-Day Moving Average coming into today.
  • STAA was 23.74% above its 50-Day Moving Average coming into today.
  • STAA was 48.64% above its 100-Day Moving Average coming into today.
  • STAA was 101.08% above its 200-Day Moving Average coming into today.
  • STAA had returned +213.87% year-to-date leading up to today’s news, versus a +9.26% return from the benchmark S&P 500 during the same period.

More Info About STAAR Surgical Company (STAA)

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye, and delivery systems to deliver lenses into the eye. The company was founded in 1982 and is based in Monrovia, California. View our full STAA ticker page with ratings, news, and more.

STAA at a Glance

STAA Current POWR Rating™
Overall POWR Rating™
STAA Current Price $33.16 4.05%
More STAA Ratings, Data, and News

STAA Price Reaction

The day of this event (Sep. 13, 2018)
STAA Closing Price$50.65 4.11%
STAA Volume567,700
112.56% from avg
Leading up to this event
STAA 1-mo return22.70%
After this event
STAA 1-day return3.28%
STAA 3-day return2.70%
STAA 5-day return1.46%

STAA Price Chart

The Top Stocks For 2019

More STAAR Surgical Company (STAA) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All STAA News
Page generated in 0.7157 seconds.